为促进外汇市场发展，支持企业管理好汇率风险，中国人民银行决定自2026年3月2日起，将远期售汇业 务的外汇风险准备金率从20%下调至0。下一步，中国人民银行将继续引导金融机构优化对企业汇率避 险服务，保持人民币汇率在合理均衡水平上的基本稳定。(中国人民银行) 开年A股并购重组逾500起 硬科技赛道活跃度居前 2026年，A股并购重组市场延续高景气态势，呈现量质齐升、政策红利集中释放、产业筑基、控制权变 更活跃等特征，成为推动上市公司高质量发展和培育新质生产力的关键路径。截至2月25日，上市公司 年初以来首次披露的并购重组交易达507起，同比增加33起；合计金额约1300亿元。其中，重大资产重 组案例20起，与去年同期持平，交易规模整体保持稳健。硬科技领域持续成为并购重组主战场，市场结 构不断优化。分板块看，主板并购数量仍占主导，占比58.3%，但同比下降超7个百分点，体现传统行 业并购从规模扩张向精益整合转型；双创板块（创业板+科创板）占比提升至近38.9%，同比增加7个百 分点，半导体、人工智能、生物医药等硬科技细分领域活跃度突出；北交所占比2.77%，以"专精特 新"定位提供差异化补充。（人民财讯） 20 ...

2月27日，口腔领域A股上市公司爱迪特（301580)以产业战略投资人身份，领投口腔手术机器人公司上 海央山医疗科技有限公司的Pre-A+轮，本轮融资还包括专业的医疗投资机构丹麓资本，央山医疗Pre-A 轮和Pre-A+轮合计完成融资近亿元。 ...

格隆汇2月26日丨爱迪特(301580.SZ)涨0.24%，报75.980元，股价创历史新高，总市值80.97亿元。 ...

证券代码：301580 证券简称：爱迪特 公告编号：2026-004 爱迪特（秦皇岛）科技股份有限公司 特别提示： 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）于 2026 年 1 月 15 日在巨潮资讯网披露了《关于持股 5%以上股东减持股份预披露公告》（公告 编号：2026-001）（以下简称"本次减持计划"）。公司持股 5%以上股东苏州 君联欣康创业投资合伙企业（有限合伙）（以下简称"君联欣康"）以及康拓有 限公司（HEALTH ADVANCE LIMITED）（以下简称"HAL"）计划自上述公 告披露之日起 15 个交易日之后 3 个月内通过集中竞价或大宗交易方式减持公司 股份，减持数量合计不超过 3,196,930 股（占公司总股本的 3.0000%）。其中， 通过集中竞价方式减持不超过 1,065,640 股（占公司总股本的 1.0000%），通过 大宗交易方式减持不超过 2,131,290 股（占公司总股本的 2.0000%）。 近日，公司收到股东君联欣康和 HAL 出具的告知函，2026 年 2 月 10 日至 2026 年 2 月 12 日期间，君联欣康和 HAL 两家通过大宗交易和 ...

Core Viewpoint - Aidi Te (301580.SZ) is progressing with the construction of its dental industrial park as planned, expected to commence production in the second half of this year, which will significantly enhance the company's overall capacity [1] Group 1 - The construction of the dental industrial park is on schedule and will begin production in the latter half of the year [1] - The company plans to release the new park's capacity in phases, aligning it with market demand and order forecasts to ensure efficient utilization of the new capacity [1] - The strategy aims to match the pace of capacity release with the growth rate of orders, ensuring orderly digestion and effective use of the increased capacity [1]

Core Viewpoint - The company, Aidi Te (301580.SZ), positions itself to serve dental laboratories and oral hospitals/clinics by providing dental materials, equipment, and comprehensive digital solutions, without directly engaging in downstream operations and production [1] Group 1 - The company focuses on technology output and capacity empowerment to deliver full-process digital solutions to downstream partners [1]

Group 1: Capacity Expansion and Production Plans - The construction of the dental industry park is progressing as planned, expected to commence production in the second half of 2026, which will significantly enhance overall capacity [2] - The company plans to release new park capacity in phases, aligning with market demand and order forecasts to ensure efficient utilization of new capacity [2] Group 2: Market Positioning and Business Strategy - The company focuses on providing dental materials, equipment, and complete digital solutions to dental labs and clinics, without directly engaging in downstream operations [2] - Continuous technical output and capacity empowerment are employed to provide comprehensive digital solutions to downstream partners [2] Group 3: Overseas Market Growth Factors - The overseas market growth is driven by three main factors: enhanced product competitiveness, solid customer relationships in Europe and the US, and effective supply chain and service advantages [3] - The company has deepened cooperation with key clients, leading to increased customer coverage and penetration rates [3] Group 4: Investment in Raw Material Supply - The investment in Jingdezhen Wanwei Powder Co., Ltd. aims to stabilize the supply chain and enhance collaborative research and development for the specific requirements of zirconia ceramic block products [4] Group 5: Profitability in Overseas Markets - The higher gross margin in overseas markets compared to domestic markets is attributed to the product structure differences and benefits from export tax rebates, which lower overall export costs [5]

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

Core Viewpoint - On February 11, a block trade of 400,000 shares of Aidi Te was executed at a price of 49.66 yuan, representing a discount of 10% compared to the market closing price of 55.18 yuan, with a total transaction value of 19.864 million yuan, accounting for 7.34% of the total trading volume that day [1]. Group 1: Transaction Details - The block trade involved a total of 400,000 shares, with a transaction value of 19.864 million yuan [1]. - The transaction price was set at 49.66 yuan per share, which is 10% lower than the market closing price of 55.18 yuan [1]. - The total trading volume for the day was significantly impacted, with the block trade accounting for 7.34% of the total trading volume [1]. Group 2: Breakdown of Transactions - Multiple transactions were recorded on February 11, with various volumes and values, all at the same price of 49.66 yuan per share [2]. - The largest single transaction recorded was for 100,000 shares, amounting to 4.966 million yuan [2]. - Other transactions included volumes of 57,000 shares (2.8306 million yuan), 48,000 shares (2.3837 million yuan), and 47,000 shares (2.3340 million yuan), all executed at the same price [2].

Core Viewpoint - The company is making significant progress in its 3D printing business, which is expected to become a new core performance driver with notable advantages [1] Group 1: 3D Printing Business Development - The company's 3D printing business is advancing well and is anticipated to be a new core performance engine [1] - The EZprint-P1 printer offers high-speed printing capabilities, completing a half-arch bridge in just 20 minutes, significantly enhancing industry production efficiency [1] - The printing materials used have a solid content of 53% and have received FDA certification, with domestic and EU certifications expected to be finalized soon [1] Group 2: Market Potential and Applications - The company believes the dental 3D printing market has vast development and growth potential [1] - The maturity of 3D printing products and technologies is continuously improving, with applications expanding into various fields such as implants and orthodontics [1] - Relevant clinical solutions have completed market validation, supporting the company's strategic direction [1] Group 3: Competitive Advantage - The company leverages a full-chain layout advantage in materials, equipment, and solutions to deepen its focus on the 3D printing business [1]